Beruflich Dokumente
Kultur Dokumente
E
+9'J.22 66061000
+91.22 6606 1200
info@ajantapharma.com
Mumbai 400 067
lndia W www.ajantaPharma.com
3'o May,2017
We have to inform that Board of Directors at its meeting held on Wednesday, 3'd May 2017,
have inter alia:
1. Approved the Audited Financial Statements (Consolidated and Standalone) for the year
ended 31st March 2017 and Audited Financial results (consolidated and standalone) for
the quarter and year ended 31st March 2017 as recommended by Audit Committee;
2. Recommended that interim dividends of Rs. 6/- per share and Rs. 7l- per share declared
atthe Board meetings held on 26b October2016 and 18th March 2017 respectively, be
considered as final dividend for the year ended 31't March, 2017 .
The report of Auditors is with unmodified opinion with respect to Audited financial results
(Consolidated and Standalone) for the quarter and year ended 31't March 2017. Declaration
to that effect is also enclosed herewith.
The Board meeting commenced at 11.00 a.m. and concluded at 2.30 p.m.
Thanking You,
Yours faithfully,
For AJ$TA PHARMA LIMITED
,a -./
--(-k'
GAURANG SHAH
AVP - Legal & Company Secretary
Encl.: a/a
Corporate ldentity Number - 124230MH1979P1C022059
Ajanta House T +91 22 6606 1000
Press Release
. EBITDA growth of 23o/o at Rs. 174 cr. against Rs. 142 cr., EBITDA at 36% of revenue.
. Profit after tax grew 5% at Rs. 114 cr. against Rs. 109 cr., PAT at 24o/o of revenue.
. Total comprehensive income grew 3% at Rs. 113 cr. against Rs. 110 cr.
"Despite the demonetization impact on the Indian pharma market, our India branded generic
sales showed resilient growth. Rupee appreciation impacted the export sales growth and the
profitability for the quarter.
Overall, we posted satisfactory results for the FY 2017 with PAT growth of 22o/o. We move
into next year with renewed vigour, resilience and focus, by crafting the strategies for
consistent growth.
Our Guwahati facility (Phase 1) was implemented in record time and it commenced
commercial production during the quarter. Ourtimely investment in world class manufacturing
facilities ensure adequate capacities to meet the sales growth."
lndia
For Q4 FY 2017 ,India's branded generic sales (excluding institution) was Rs. 133 cr. posting
growth ot 13%. For FY 2017, itwas Rs. 593 cr. posting healthy growth of 15%.
For Q4 FY 2017, Total India sales (including institution) was Rs. 140 cr., up 12o/o. For FY 2017,
it was Rs. 614 cr., up 12o/o.
Exports
During Q4 FY 2017, Export sales were Rs. 317 cr., posting growth of 60/o. Africa contributed
Rs. 132 cr., de- growth of 24o/o, Asia contributed Rs. 137 cr., grovuth of 15o/o and US contributed
Rs. 45 cr. growth of 838%.
w
1( nrurvranr)]
In US, we received I ANDA final approvals, commercialized 7 products and filed 8 ANDAs
with US FDA during FY 2017. With this, company has 12 products commercialized out of 17
final ANDA approvals, has 2 tentative approvals and 15 ANDA awaiting approval with US FDA
at the end of FY 2017. company plans to file 12-15 ANDAs during Fy 2o1rg.
R&D
Company enhanced its R&D spend to 8% of operating revenue both during Q4 & Fy 2017.
For Q4, R&D expenses were Rs. 39 cr. (Q4 FY 2016 Rs. 36 cr.), whereas for FY 2017, R&D
expenses were Rs. 153 cr. (FY 2016 Rs. 106 cr.).
Company's state of the art R&D centres for formulation development and API are located at
Mumbai, having a team of 800+ scientists. Company has 7 world class manufacturing facilities
located in India and Mauritius.
For last 5 years, company has posted healthy performance with its consolidated total income
growing at21o/o CAGR and net profit at 46% CAGR.
Page2 of 2
Corporate ldentity Number - 124230MH1979ptC022059
T +91 22 6606 1000
@ aiantaphnrmalimited Ajanta House,
Charkop, Kandivli West,
Mumbai400 067
F +9122660167200
E info@ajantapharma.com
lndia W www.ajantapharma.com
Statement of Consolidated Audited Financial Results for the quarter and year ended 31 March 2017
t in Crore
Particulars 3 months ended Year Ended
3'U03t2017 31t12t2016 31 t03t2016 3'U03t2017 31 t03t2016
ncome
iales
lndia 139.61 1 54.00 124.12 613.74 549.35
Outside India 316.51 361.02 299.95 1 .31 8.87 1,177.52
)ther operating income 20.69 18.09 6.53 69.03 22.50
levenue from operations 476.81 533.1 1 430.60 2,OO1,64 1,749,37
)ther lncome 7.39 19.19 5.05 23.86 21,15
Total Income 479.20 5s2.30 435.65 2,025.50 1,770.52
:xpenses
lost of materials consumed 80.1 9 97.72 101 .95 377.85 400.09
)urchases of stock-in-trade 7.14 29.00
19.41 47.36 63.01
lhanges in inventories of finished goods,
4.93 ('t0.71 135.47) (10.62 (49.27',;
vork-in-nrnorx< end <tmlr-in-tr:ia
:mptoyee benefits expense 75.50 77.44 68.84 295.42 256.64
rinance costs
0.89 0.82 1.12 3.49 4.89
)eoreciation and amortisation exDense 18.92 1 5.30 11.42 61.21 44.43
)ther exoenses 147.65 17',t.27 124.53 602.62 491.U
Total exoenses 335.22 371.25 301.39 1,377.33 1,211.63
troflt before tax 143.98 181.05 134.26 648.17 558.89
fax Expense
Current Tax 30.67 40.94 18.70 157.49 14't.17
Deferred Tax rc.7'l (2.49) 6.60 (16.1 s 2.11
Profit for the period '114,O2 142.60 10E.96 s06.83 4't5.61
Other Comprehensive Income (OCl)
Items that will not be reclassified to Drofit & loss {net) 0.06 (0.06 (0.06 (0.1 1 (0.23
Items that wi[ be rec]assified to orofit & loss (net) (1.03', (0.87 1.23 Q.42 5.58
Other Comprehensive Income for the vear, net of tax o.97'. (0.93) 1.17 (2.s31 5.35
fotal Comorehensive Income for the oeriod 1 13.05 141.67 I 10.13 504.30 420.96
Paid-up Equity Share Capital (Face value of ( 2 each) 't7.69 17.69 17.69 17.69 17.69
Sther Equity 1,549.99 1,173.17
iarnings Per Share (Face vatue of t 2 each)
Basic - in ? 12.96 16,21 12.38 57.59 47.23
Dituted - in t 12.95 16.20 12.38 57.58 47.23
Notes :
1 . Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 3 tlay 7017.
2. Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published year to date figure upto
the end of third quarter of relevant financial year.
3. Board of Directors have approved 2nd interim dividend of ( 7 per equity share which was paid on 30 March 2017, in addition to ( 6 per equity share,
which was paid as 'lst interim dividend in November 2016. The Board has recommended total of interim dividend of ( 13 per equity share for N 2016-17
to be considered as final dividend.
4. Company has adopted Indian Accounting Standards ("lnd AS") from 1 April 2016 (transition date being 1 Aprit 2015). The impact of transition has been
accounted for in opening reserves and the comparative periods have been restated accordingly.
5. The consolidated audited financiat results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared
as per lnd AS 110 on Consolidated Financial Statements. There is no minority interest,
6. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
7. There are no exceptionat items,
8, Reconciliation of net profit and reserves as per Ind AS and Indian GMP for the relevant periods of the previous year is as follows:
{ in Crore
a) Fair valuation of Financial Assets - Under Indian GMP, financial assets were measured at lower of cost and realisation value, Under Ind AS such
financiat assets are recognised and measured at fair value. lmpact of fair value changes as on the date of transition, i.e., 1st April 20i5, is recognised
in reseryes and changes thereafter are recognised in statement of Profit and Loss or Other Comprehensive Income, as the case may be.
b) Emptoyee benefits - Actuarial gains and losses on defined benefit plans: Under lndian GMP att actuariat gains and losses were recognised in
statement of Profit and Loss. Under Ind AS these are recognised in Other Comprehensive Income,
c) Others - Other adjustments mainty comprises of provision for expiry goods pertaining to earlier years, which has resutted in charge to the reserves,
on the date of transition, with consequential impact to the statement of profit and loss for the subsequent periods.
d) Deferred Tax - The impact of transition adjustments together with Ind AS mandate of using batance sheet approach (against profit and loss approach
in previous GMP) for computation of deferred taxes has resulted in charge to the reserves, on the date of transition, with consequential impact to the
statement of profit and loss for the subsequent periods.
9, Statement of Assets and Liabitities { in Crore
31 t03t2017
1,173.17
1,1 90.86
5(tt lliiLi'rBI
Page 2 of 3 trs tn
Or
10. During the quarter, Nil (year to date 3,750) equity shares of ( 2 each, fully paid up, were altotted upon exercise of vested options pursuant to the
Employees Stock Options Scheme, 201'1.
11. Board of Directors in their meeting held on'18 t\rtarch 2017 approved the amalgamation of Gabs Investments Private Limited ('Gabs') with the
Company in consideration for Equity shares of the Company. Gabs hotds 83,92,262 equity shares in the Company, representing about 9.54% of the totat
paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amatgamation is subject to approval of
shareholders of both the Companies and other regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial
statements.
12. The Standalone Audited Financial Results are available on the companys website www,ajantapharma.com
1 3. previous period,s figures have been regrouped wherever necessary.
By order of the Board
For Ajanta Pharma Ltd.
s(;nEi$jl'')F
Qr"l'C
Page 3 of 3
To
The Board of Directors of
AJANTA PHARMA LIMITED
(f, I\%'
3(nc,
ryDlc
f,''liS/t
e\ ./L,il
6;y/ Page 1 of 2
701, Business Suites I, S.V. Boad, Santacruz (W), Mumbai - 400 054, India.Tel: +91 222600n02Fax:+91 22 2600 7706 Email : info@sskpa.com, Web : www.sskpa,com
KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS
5. In our opinion and to the best of our information and according to the
explanations given to us and based on the consideration of the reports of the
other auditors referred to in paragraph 4 above, the Statement:
a. inctudes the financial resutts of the fottowing subsidiaries:
i.Ajanta Pharma (Mauritius) Limited ("APML")
ii.Ajanta Pharma Nigeria Limited
iii.Ajanta Pharma USA Inc.
iv. Ajanta Pharma Phitippines Inc.
v. Ajanta Pharma (Mauritius) International Limited
(Whotty owned subsidiary of APML)
6. The Statement includes the resutts for the quarter ended 31 March 2017, being
the balancing figure between audited figures in respect of the futl financiatyear
and the pubtished unaudited year to date figures up to the third quarter of the
current financial year, which were subject to limited review by us.
Nilesh Parekh
Partner
M. No. 33528
Page 2 of 2
701, Business Suites 9, S. V. Road, Santacruz (W), ft,lumbai - 400 054, India.Tel: +91 2226007702 Fax:+91 2226007706 Email : info@sskpa.com, Web : wwusskpa.com
T +91 22 6606 1O0O
@ nimtnphnrmalimited Ajanta House,
Charkop, Kandivli West,
Mumbai400 067
F +91 2266061200
E info@ajantaPharma.com
lndia W www.ajantaPharma.com
Statement of Standalone Audited Financial Results for the quarter and year ended 31 March 2017
{ in Crore
Particulars 3 months ended Year Ended
31 t03t2017 3',U12t2016 31 t03t2016 31 t03t2017 t1 t03t2016
lncome
iates
India 139.61 1 54.00 124.12 613.74 549.35
Outside lndia 258.20 336.51 275.87 1,139.94 1,001.75
)ther oDeratinq income 20.69 1 8.09 6.53 69.03 22.50
Revenue from operatlons 418.50 508.60 406.52 1,822.71 't.573.60
f,ther Income 7.36 51.08 43.28 66.95 &.E7
Total lncome 425.86 559.5E 449.80 1,889.65 1.660.47
Expenses
:ost of materials consumed 79.14 96.93 101.26 373.31 397.21
turchases of stock-in-trade 5.55 18.10
1 18.36 59.23 57.81
3hanges in inventories of finished goods,
(s.ee) 12.79 (18.04) 7.29 (41.01
lark-in-nrmra<c anal <f trk-in-f ra.la
:mptoyee benefits expense 69.09 69.28 63.34 269.78 235.03
.inance costs 0.74 0.59 0.92 2.83 4.19
)epreciation and amortisation expense 18.87 14.73 1 1.55 59.48 42.68
)ther expenses 1 I 8.82 t36.00 110.79 477.09 402.00
Total expenses 296.22 t48.42 288.18 1,249.01 1,O97.91
lrofit before tax 129.64 211.26 16'1.62 640.65 s62.56
Tax Expense
Current Tax 19.45 39.00 16.82 136.98 131.89
Deferred Tax 2.22 1.28 6.81 3.86 8.72
trofit for the period 107.97 170.94 137.99 499.81 121.95
)ther Comprehensive Income (OCl)
tems that will not be reclassified to profit & loss (net) 0.06 (0.06 (0.06) (0.1 1 (0.23)
tems that witl be reclassified to Drofit & loss (net)
)ther Comprehensive Income for the vear, net of tax 0.06 (0.06' (0.06 (0.1 r ) (0.231
fotal Comprehensive Income for the period 108.03 170.92 't37.93 499.70 421,72
)aid-up Equity Share Capital (Face value of ( 2 each) 17.69 17.69 17.69 17.69 17.69
)ther Equity 1,486.25 1,114,01
:arnings Per Share (Face value of ( 2 each)
Basic - in ( 12.27 19.42 1 5.68 56.79 47.95
Dituted - in ? 12.27 19.42 1 5.68 56.78 47.95
Notes :
1. Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 3 llay 2017.
2. Figures pertaining to last quarter are balancing figures between audited figures in respect of futl financial year and pubtished year to date figure upto
the end of third quarter of relevant financial year.
3. Board of Directors have approved 2nd interim dividend of t 7 per equity share which was paid on 30 lrlarch 2017, in addition to { 6 per equity share,
which was paid as lst interim dividend in November 2016. The Board has recommended total of interim dividend of ( 13 per equity share for F'( 2016-17
to be considered as final dividend.
4. Other income includes : 3 months ended Year Ended
31 t03t2017 31 I 1212016 31 t03t2016 31 t03t2017 31 t03t2016
)ividend from subsidiaries (( in Crore) 9.80 33.38 40.17 43.18 66.91
5. Company has adopted Indian Accounting Standards ("lnd AS") from 1 April 2016 (transition date being 1 Aprit 2015), The impact of transition has been
accounted for in opening reserves and the comparative periods have been restated accordingly.
6. The Company operates exclusively in one reportabte business segment i.e,, "Pharmaceuticals".
7. There are no exceptional items.
8. Reconciliation of net profit and reserves as per Ind AS and Indian GAAP for the relevant priods of the previous year is as fotlows:
{ in Crore
Profit Reconcitiation Other Equity
Nature of adjustments 3 months endec Year ended As at
31 t03t2016 31 t03t2016 31 t03t2016
trofit for the period / Other Equity per Previous Indian
as GAAP 1 35.71 414.48 1,107.10
'air Value of Financial Assets (refer note'a') 1.60 4.45 10.38
imployee Benefits - Actuarial Gain/(Loss) (refer note'b') 0.19 0.35
)thers (refer note'c') 1.47 6,45
)eferred Tax (refer note'd') (0.e8) (3.78) (3.47
fotal 2.28 7,47 6.91
Profit for the oeriod before OCI / Othellouitv as oer Ind AS 't37.99 421.95 1,114.O1
Page 1 of 3
I//,v ffi.
ir-x ?- qql v\^l \_,/I .
I
)
ilr 'uu*roJ
\?
h#
m
'>)
124230MH1979P1 c022059
T +91 22 6606 1000
@ niantnphnrmalimited Ajanta House,
Charkop, Kandivli West,
Mumbai 4O0067
F +91 2266067200
E info@ajantapharma.com
lndia W www.ajantapharma.com
a) Fair valuation of Financial Assets - Under Indian GAAP, financial assets were measured at lower of cost and realisation value. Under Ind AS such
financial assets are recognised and measured at fair value, lmpact of fair value changes as on the date of transition, i.e,, 1st April 2015, is recognised in
reseryes and changes thereafter are recognised in statement of Profit and Loss or Other Comprehensive Income, as the case may be.
b) Employee benefits - Actuarial gains and losses on defined benefit plans: Under Indian GAAP all actuarial gains and losses were recognised in
statement of Profit and Loss. Under Ind AS these are recognised in Other Comprehensive Income.
c) Others - Other adjustments mainly comprises of provision for expiry goods pertaining to earlier years, which has resulted in charge to the reseryes, on
the date of transition, with consequential impact to the statement of profit and loss for the subsequent periods.
d) Deferred Tax'The impact of transition adjustments together with Ind AS mandate of using batance sheet approach (against profit and loss approach
in previous GMP) for computation of deferred taxes has resulted in charge to the reseryes, on the date of transition, with consequential impact to the
statement of profit and loss for the subsequent periods.
9. Statement of Assets and Liabitities { in Crore
Particulars 31 t03t2017 31 t03t2016
dssErs
[on-Current Assets
Property, Plant and Equipment 566.97 429.08
Capital Work-in-Progress 338.03 238.42
Other Intangible Assets 5.96 3.75
Intangible assets under devetopment 1.23 1.38
Financial Assets
Investments 17.26 17.25
Others 9.09 9.09
Other non-current assets 13.93 1 6.30
Total Non-Current Asset! 952.47 715.27
:urrent Assets
Inventories 179.28 't89.78
Financial Asets
lnvestments 181.56 76.78
Trade Receivabtes 336.00 350.48
Cash and cash equivalents 4.8',1 19.49
Other Bank balances 4.12 1.95
Others 1.24 0.71
Current Tax Asets (Net) 11.23 17.63
other current assets 54.1 5 4',t.60
Total Current Asset! 772.39 698.42
Total Asset! 1,724.86 1,413.69
:QUTTY AND LIABILIT]ES
:QUfTY
Equity Share Capital 17.69 17.69
Other Eouitv 1.446.25 1,1't4.01
Total Equity 1,503.94 1,131.70
-IABILlTIES
{on-Current Liabilities
Financial Liabitities
Borrowings 1 3.82
Other financial liabitities 0.09 0.45
Provisions 3.t5 2.59
Deferred tax tiabitities (Net) 27.38 23.58
Total Non-Current Llabllities 30.62 40.44
lurrent Llabllltles
Financial Liabilities
Borrowings 5.53 34.47
Trade Payables 1 38.78 145.04
Other financial liabilities 25.28 40.07
Other current tiabilities 7.91 10.61
Provisions 12.80 1 1.36
Total Current Liabillties 190.30 241.55
Total Llabllltles 220.92 281,99
Total Equity and Liabilitie: 1,724.86 1,413.69
Page 2 of 3
10. During the quarter, Nil (year to date 3,750) equity shares of ( 2 each, futly paid up, were allotted upon exercise of vested options puruant to the
Employees Stock Options Scheme, 201'1.
11. Board of Directors in their meeting held on 18 lr{arch 2017 approved the amalgamation of Gabs Investments Private Limited ('Gabs) with the
Company in consideration for Eguity shares of the Company. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of the total
paid up capital, against which Company will issue same number of shares to the shareholders of Gabs. Amalgamation is subject to approval of
shareholders of both the Companies and other regulatory authorities as prescribed in law. Hence, no effect of the same is given in the financial
statements.
'12. Previous period's figures have been regrouped wherever necessary,
\n^r*
Yogesh M. Agrawal
Y
Mumbai, 3li^ay 2017 lvtanaging Director
Page 3 of 3
To
The Board of Directors of
AJANTA PHARMA LIMITED
4. Based on our audit conducted as above, in our opinion and to the best of our
information and according to the exptanations given to us, the Statement:
(i) is presented in accordance with the requirements of Regutation 33 of the
SEBI (Listing Obtigations and Disctosure Requirements) Regutations, 2015
read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 Juty 2016; and
(ii)give a true and fair view, in conformity with the aforesaid Ind AS and
other accounting principtes generatty accepted in lndia, of the net profit
(financial performance including other comprehensive income) and other
fina for the year ended 31 March2017.
Page 1 of 2
701, Business Suites 9, S, V. Road,' '400 054, India.Tel: +91 2226007702 Fax:+91 2226007706 Email : info@sskpa.com, Web : www.sskpa.com
KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS
5. The Statement includes the results for the quarter ended 31 March 2017,
being the batancing figure between audited figures in respect of the futt
financial year and the pubtished unaudited year to date figures up to the
third quarter of the current financial year, which were subject to limited
review by us.
Nitesh Parekh
Partner
M. No. 33528
Page 2 of 2
701, Business Suites 9, S.V. Road, Santacruz (W), lllumbai - 400 054, lndia.Tel: +91 22 2600 7702 Far+91 2226007706 Email : infoQsskpa.com, Web l wwwsskpa,com
+9L22 5606 1000
@ Ajanta House, T
ninntapharmatimited Charkop, Kandivli West, F +9122 6606 1200
Mumbai 400 067 E info@aja ntapharma.com
lndia W www.ajantapharma.com
3td May,2017
Dear Sirs/Madam,
Sub.: Declaration under Regulation 33(3Xd) of SEBI (Listing Obligations and Disclosure
Requirements) (Amendment) Regulations, 2016 and SEBI Circular No.
clR/cFD/cMD/56/2016
DECLARATION
ln compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2016 as amended by the SEBI (Listing Obligations
and Disclosure Requirements) (Amendment) Regulations, 2016 and SEBI Circular No.
Cf R/CFD/CMD15612016 dated 27th May,2016,1 hereby declare that M/s. Kapoor & Parekh
-
Associates, Chartered Accountants (FRN 104803W), Statutory Auditors of the Company,
have issued an Audit Report with unmodified opinion on Audited Financial Results
(Standalone and Consolidated) of the company for the quarter and year ended 31st March,
2017.
Thanking you,
,:fi,z ',J
Yours faithfullv.